THALES
23.5.2024 09:01:29 CEST | Business Wire | Press release
The Mauritius Prime Minister's Office (PMO) has entrusted the consortium led by Thales, which includes the leading Mauritian-grown IT provider Harel Mallac Technologies (HMT), with a crucial step toward developing a comprehensive National ID system to improve citizen services and bolstering identity security. This partnership sets the foundations for the next generation digital journey of Mauritius, fully aligned with the country’s 2030 digital strategy.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240523106005/en/
©Thales
This ambitious modernisation effort draws on Thales experience from 300 government projects worldwide, and ensures that field-proven technology can be associated for timely delivery and reliable project execution. It is a long-term partnership providing consistent and expert support in all key components of the identity scheme, from citizen enrolment to physical and digital ID issuance. This end-to-end approach effectively meets future evolutions as well as potential identity threats.
As part of the 10-year contract Thales is providing a powerful and modular Identity Management System to securely issue cutting-edge eID cards and its mobile companion, the Digital ID Wallet. The solution assures comprehensive trust and privacy in daily interactions between public entities and individuals. The user experience is at the core of this modernisation drive, illustrated by the wider range of new functionalities and services it brings to citizens.
The citizen’s journey starts with a frictionless enrolment process, which can be initiated online from the comfort of home to save citizens time when visiting the enrolment centre. Once enrolled, the holder will receive a new eID card which relies on the latest Thales embedded software and advanced security features, including high resolution colour photo1, to effectively combat forgery and identity theft. For more convenience, self-service kiosks will be installed at dedicated spots to enable users to update their ID cards’ information (with new address, etc) and manage the PIN code associated with the digital certificates stored in their card.
Citizens can also activate their Digital ID Wallet, a secure mobile application where they can securely store and share digital identity documents. The wallet will initially include digital versions of the identity card and will subsequently contain other official documents such as birth and marriage certificates. These may then be shared both online and in-person. Citizens will also be able to digitally sign documents with a one-time certificate as well as log in to online government services by using their digital wallet. For service providers (public administrations, banks, retailers, universities, etc…) it will be a simpler and more secure way to verify identities. Citizens’ control over their personal data is guaranteed thanks to stringent data privacy and consent management mechanisms.
Mauritius identity cards production will benefit from Thales factories’ sustainability action plan, which aims to reduce the carbon footprint by utilising 100% renewable electricity, optimising energy consumption and minimising waste. As a complement to this approach, the Mauritius project is part of Thales' offsetting program which supports sustainable initiatives2 worldwide (selected in collaboration with Climate Impact Partner) by offsetting the carbon emissions from all its travel and ID solutions.
During the official launching on 26th February 2024 of the national ID card at the Sir Harilal Vaghjee Memorial Hall, Government Centre, Port Louis, it was stated that:
“The purpose of modernising the present system with sophisticated and next generation technology is to enable new services while increasing citizen security and convenience. The next-generation ID system will lay the foundation for supporting the country's digital transformation, benefiting all stakeholders and fostering economic growth.”
“With this implementation, blending ID cards and digital identity, Mauritius fully leverages the best of both worlds, offering the optimal combination of security and ease,” says Youzec Kurp, VP Identity and Biometrics Solutions at Thales. “The new Mauritius ID system stands as one of the most advanced and marks the first implementation of a fully interoperable Digital ID Wallet in Africa, adhering to international ISO standards. This positions Mauritius amongst the pioneer countries in identity solutions worldwide.”
1 The new e-document incorporates latest generation of embedded software together with advanced physical features such as Thales Colour Laser Shield technology (high resolution colour portrait) ensuring state-of-the-art protection against counterfeiting for both blank and personalised documents, True Vision (high resolution true-colour UV picture), transparent window element with the holders’ ghost image, and Secure Surface 3D tactile features combining movement and light reflection.
2 Example of supported projects in 2023: Vichada Afforestation in Colombia, Aqua Clara Water Filters in Kenya, Renewable Energy Portfolio worldwide.
About Thales
Thales (Euronext Paris: HO) is a global leader in advanced technologies specialized in three business domains: Defence & Security, Aeronautics & Space, and Cybersecurity & Digital identity.
It develops products and solutions that help make the world safer, greener and more inclusive.
The Group invests close to €4 billion a year in Research & Development, particularly in key innovation areas such as AI, cybersecurity, quantum technologies, cloud technologies and 6G.
Thales has close to 81,000* employees in 68 countries. In 2023, the Group generated sales of €18.4 billion.
* These figures exclude the ground transportation business, which is being divested.
PLEASE VISIT
Thales Group
Digital Identity & Security
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240523106005/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
